

# Indonesian Oral Biology Association

# Journal of Molecular Oral Biology and Dental Sciences

http://jurnal.pdgi.or.id/index.php/jmobds ISSN: xxxx-xxxx (Online)



# RESEARCH ARTICLE

# **ARTICLE TITLE**

(Article Title, English, Max. 15 Words, Palatino Linotype, 14 pt, Bold, Space 1, Center)

# Author's Name<sup>1</sup>, Author's Name<sup>2,3§</sup>

- <sup>1</sup> Author's Affiliation (Department, Faculty, University, City, Country)
- <sup>2</sup> Author's Affiliation (Department, Faculty, University, City, Country)

§Corresponding Author Email: author@email.com Phone: +62-xxx-xxxxx

Received date: xxx xx, xxxx; Revised date: xxx xx, xxxx; Accepted date: xxx xx, xxxx

## **KEYWORDS**

Consist of five phrases arranged according to the variable or key term to be emphasized, separated by commas. The first phrase should begin with a capital letter, while subsequent phrases should be in lowercase. (Times New Roman, 8 pt)

## **ABSTRACT**

Abstracts written in English must provide a complete summary of the article's content, formatted in Times New Roman, 9 pt. The abstract should be a single continuous paragraph not exceeding 300 words, and structured using the following headings: Introduction:... Objective:... Methods:... Results:... Conclusion:...

DOI:

#### Citation

Author's Last Name, Author First Name Initial; Other Author's. Article title. J Mol Oral Biol Dent Sci. 20xx; Vol (Issue): Page.



## INTRODUCTION (Cambria, 11 pt, Bold)

The introduction should highlight the novelty and significance of the problem addressed, providing a clear overview of the issue and explaining its importance. Summarize several solutions from prior research, identify gaps or limitations in these studies, or highlight advantages that can be applied to the current problem. Conclude the introduction with specific research objectives, including any predefined hypotheses. Each paragraph should comprise at least two sentences. The introduction, like the rest of the article, should not include subheadings and must cite a minimum of 15 references. (Times New Roman, 10 pt)

## METHOD (Cambria, 11 pt, Bold)

The methods section should clearly describe the study design, population, sampling techniques, research instruments, study duration, and location. It must also detail the data collection process, including recruitment period, exposure, follow-up (if applicable), and the data analysis methods, including statistical procedures used. (Times New Roman, 10 pt)


## **RESULT** (Cambria, 11 pt, Bold)


The results section should present the primary findings of the study, aligned with the study's title and objectives. Data should be displayed using tables or figures, each accompanied by descriptive text referencing these visual elements. Tables and figures must be embedded within the manuscript, with special attention to histology, histopathology, and SEM images where arrows should be used to highlight key details. Use Times New Roman, 10 pt for the main text.

Table and figure captions should be numbered consecutively with Arabic numerals and formatted in Times New Roman, 8 pt, single-spaced. To enhance manuscript quality, submit tables (in Microsoft Word or Excel format) and figures (in JPEG format with a minimum resolution of 300 dpi) as separate files. Please refer to the provided examples for proper table and figure presentation.

**Table 1.** Table titles should begin with a capital letter only for the first word, be justified, and formatted in Times New Roman, 9 pt. Tables must be positioned within the main text close to their initial citation.

	Variable	Variable
Variable	Example Data	Example Data
Variable	Example Data	Example Data





**Figure 1.** Figure titles should begin with a capital letter only for the first word, be justified, and formatted in Times New Roman, 9 pt. Figures must be positioned within the main text close to their initial citation.



#### **DISCUSSION** (Cambria, 11 pt, Bold)

The discussion section should interpret the research findings by synthesizing, analyzing, and comparing them with relevant existing literature. Repetition of content from the Introduction, Methods, or Results sections is not allowed. References to Tables and Figures should be clearly indicated by their respective numbers. The discussion should be more comprehensive than the Introduction, maintaining consistency throughout the manuscript from the title to this section. At the conclusion of the discussion, authors must address the study's limitations and provide recommendations for future research. (Times New Roman, 10 pt)

## **CONCLUSION** (Cambria, 11 pt, Bold)

The Conclusion should address the research questions without presenting statistical data, instead offering a concise summary of the key findings. It should clearly reflect the outcomes related to the stated research objectives and discuss the broader implications of the study. (Times New Roman, 10 pt)

**Acknowledgements** (if necessary): Acknowledgements must be restricted to declarations of financial support, such as research grants or institutional funding, with clear identification of the individual or organization providing the support. Non-financial contributions, technical assistance, or other informal support should not be included in this section. (Times New Roman, 9 pt)

**Author Contributions:** Conceptualization: X.X. and Y.Y.; Methodology: X.X.; Software: X.X.; Validation: X.X., Y.Y., and Z.Z.; Formal analysis: X.X.; Investigation: X.X.; Resources: X.X.; Data curation: X.X.; Writing—original draft preparation: X.X.; Writing—review and editing: X.X.; Visualization: X.X.; Supervision: X.X.; Project administration: X.X.; Funding acquisition: Y.Y. All authors have reviewed and approved the final version of the manuscript. (Times New Roman, 9 pt)

**Funding:** Please include a statement regarding funding, such as "This research did not receive any external funding," or "This research was funded by [GRANTOR NAME] under grant number [XXX]," and/or "This article processing charge (APC) was funded by [XXX]." Ensure all funding information is accurate and uses the standardized spelling of the funding agency as found at <a href="https://search.crossref.org/funding">https://search.crossref.org/funding</a>, since any errors may affect future funding opportunities. (Times New Roman, 9 pt)

Ethics Approval: For research involving human participants, please state: "This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of [NAME OF INSTITUTION] (protocol number XXX; approval date)." For animal studies, use: "The animal study protocol was approved by the Ethics Committee of [NAME OF INSTITUTION] (protocol number XXX; approval date)." If ethical approval was not required, provide a detailed explanation, for example: "Ethics review and approval were not applicable due to [reason]." For studies not involving humans or animals, simply state: "Not applicable." (Times New Roman, 9 pt)

Institutional Review Board Statement: If applicable, please include the institutional review board (IRB) statement along with the approval number in this section. This statement is not necessary if your study does not require ethics approval. Note that the Editorial Office may request additional information. For research involving human participants, please include: "This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of [NAME OF INSTITUTION] (protocol number XXX; approval date)." For animal research, use: "The animal study protocol was approved by the Institutional Review Board (or Ethics Committee) of [INSTITUTE NAME] (protocol number XXX; approval date)." If ethics approval was not obtained, provide a detailed justification, for example: "Ethics review and approval were not required for this study due to [reason]." For studies involving neither humans nor animals, please state: "Not applicable." (Times New Roman, 9 pt)

**Informed Consent Statement:** All research articles involving human participants must include a statement regarding consent. Please add one of the following as appropriate: "Informed consent was obtained from all subjects involved in this study," or "Patient consent was not provided due to



[detailed rationale]," or "Not applicable" if the study does not involve humans. While this statement may be omitted for non-human research, written informed consent for publication must be obtained from all identifiable patients (including the patients themselves). If applicable, please include: "Written informed consent has been obtained from the patient for publication of this research." (Times New Roman, 9 pt)

**Data Availability Statement:** Journal of Molecular Oral Biology and Dental Sciences (JMOBDS) encourages all authors to share access to their research data in compliance with relevant ethical standards. Please include information on where the data supporting your findings can be accessed, including links to any publicly archived datasets used or generated during the study. If no new data were produced, or if data cannot be shared due to privacy or ethical restrictions, a clear statement explaining this must still be provided. (Times New Roman, 9 pt)

**Conflict of Interest:** Authors must disclose any potential conflicts of interest or declare, "The authors declare no conflicts of interest." Any personal circumstances or affiliations that could be perceived to influence the interpretation or presentation of the research findings should be clearly identified. Additionally, the role of the funding source in study design, data collection, analysis, interpretation, manuscript preparation, or publication decisions must be disclosed. If the funder had no involvement in these aspects, please state: "The funder had no role in study design; data collection, analysis, or interpretation; manuscript writing; or the decision to publish the results." (Times New Roman, 9 pt)

## **REFERENCES** (Cambria, 11 pt, Bold)

- 1. References should consist of both primary and supplementary sources. At least 80% of primary references must be drawn from reputable journals published within the last 10 years, while supplementary references, also from the past decade, may constitute up to 20% of the total. Furthermore, a minimum of 80% of all references should be from international sources, with no more than 20% originating from local sources.
- 2. References must be formatted using Vancouver style with superscript numbering. Consecutive references should be indicated by a hyphen (e.g., 1–3) without further explanation. Each citation number is placed at the end of the sentence, following the period. Use of reference management software such as Mendeley® or Zotero is recommended.
- 3. The total number of references should exceed 20.
- 4. Journal references must include a DOI when available, formatted as a clickable link (e.g., https://doi.org/10.1128/JCM.02303-07)
- 5. Use Times New Roman, font size 10 pt for the main manuscript text.

Please adhere closely to all the examples provided below:

#### Article:

Roddy P, Goiri J, Flevaud L, Palma PP, Morote S, Lima N. et al., Field evaluation of a rapid immunochromatographic assay for detection of *Trypanosoma cruzi* infection by use of whole blood. J Clin Microbiol. 2008; 46: 2022-7. Doi: https://doi.org/10.1128/JCM.02303-07

#### Book:

Parija SC. Textbook of medical parasitology. 3rd ed. All India Publishers and Distributors. 2008.

# Chapter in a book:

Nesheim M C. Ascariasis and human nutrition. In ascariasis and its prevention and control, D. W. T. Crompton, M. C. Nesbemi, and Z. S. Pawlowski (eds.). Taylor and Francis, London, U.K. 1989, pp. 87–100.

#### **Dissertation/Thesis/Essay:**

Sinkiewicz G. *Lactobacillus reuteri* in health and disease [Dissertation]. Holmbergs, Malmö: Malmö University; 2010

#### Part of Website/Monograph:

Diabetes Australia. Gestational diabetes [Internet]. Canberra (ACT): Diabetes Australia; 2015 [updated 2015; cited 2017 Nov 23]. Available from: https://www.diabetesaustralia.com.au/gestational-diabetes

#### **Conference Paper:**

Bengtsson S, Solheim BG. Enforcement of data protection, privacy and security in medical informatics. In: Lun KC. Degoulet P. Piemme TE, Reinhoff O, editors. MEDINFO 92.



Proceedings of the 7th World Congress on Medical Informatics. 1992 Sep 6-10; Geneva, Switzerland. Amsterdam: North Holland; 1992. p. 1561-5.

